natgillin/translations-raw huggingface dataset:
thrombocytopenia (< 100,000 cells/mm3) prothrombin time > 1.2 times control, or International Normalized Ratio (INR) ≥ 2.0 severe hypertension (systolic blood pressure > 200 mm Hg or diastolic blood pressure > 110 mm Hg on antihypertensive therapy)
trombocitopenijo (< 100.000 celic/mm3); protrombinskim časom > 1,2-krat večjim od kontrolne vrednosti ali mednarodnim normaliziranim količnikom (INR) ≥ 2,0; hudo hipertenzijo (sistolični krvni tlak > 200 mm Hg ali diastolični krvni tlak > 110 mmHg ob antihipertenzivnem zdravljenju);
Thrombocytopenia (G3/4: 0.6%); Febrile neutropenia
Trombocitopenija (S3/4: 3 %)
Thrombocytopenia (G3/4: 1.6%);
preobčutljivost (S3/4: 0,6 %)
Thrombocytopenia (G3/4: 1.6%);
Trombocitopenija (S3/4: 3 %)
Thrombocytopenia (G3/4: 3%)
trombocitopenija (S 3/4: 3 %)
Thrombocytopenia (G3/4: 3%)
Trombocitopenija (S3/4: 3 %)
Thrombocytopenia (G3/4: 8.8%); Febrile neutropenia
Kašelj (S3/4: 0 %)
Thrombocytopenia (G4: 0.2%)
trombocitopenija (S 4:
Thrombocytopenia (G4: 0.2%)
trombocitopenija (S4: 0,2 %)
Thrombocytopenia (G4: 0.2%)
trombocitopenija (S4: 0,2%)
Thrombocytopenia (G4: 0.5%)
febrilna nevtropenija
thrombocytopenia (low blood platelet counts);
trombocitopenijo (znižano število trombocitov v krvi);
Thrombocytopenia (low number of blood platelets)
trombocitopenija (nizko število trombocitov)
Thrombocytopenia (platelet count decreased)
Trombocitopenija (zmanjšanje števila trombocitov)
Thrombocytopenia (some very rare cases were severe with platelet counts less than 5,000 per mm3).
Trombocitopenija (nekaj zelo redkih primerov s številom trombocitov pod 5.000 na mm3).
Thrombocytopenia (some very rare cases were severe with platelet counts less than 5.000 per mm3).
Trombocitopenija (nekaj zelo redkih primerov s številom trombocitov pod 5.000 na mm3).
Thrombocytopenia < 25,000/mm3
Trombocitopenija < 25.000/mm3
Thrombocytopenia a
trombocitopenijaa
Thrombocytopenia and Immunogencity related to GP IIb/IIIa inhibitors
Trombocitopenija in imunogenost, povezani z zaviralci GP IIb/IIIa
Thrombocytopenia and Neutropenia
Trombocitopenija in nevtropenija
thrombocytopenia bone disease after exclusion of other causes such as Vitamin D deficiency hepatomegaly or splenomegaly
trombocitopenija, bolezen kosti, ko smo izključili druge vzroke zanjo, kot npr. pomanjkanje vitamina D, hepatomegalija ali splenomegalija.
Thrombocytopenia f
Trombocitopenijaf
Thrombocytopenia Febrile neutropenia Anaemia Pancytopenia Granulocytopenia
trombocitopenija febrilna nevtropenija anemija pancitopenija granulocitopenija
Thrombocytopenia has been reported commonly in patients receiving filgrastim.
Pri bolnikih, ki so dobivali filgrastim, so pogosto poročali o trombocitopeniji.
Thrombocytopenia has been reported commonly in patients receiving filgrastim.
Pri bolnikih, ki so prejemali filgrastim, so pogosto poročali o trombocitopeniji.
Thrombocytopenia has been reported commonly in patients receiving filgrastim.
Pri bolnikih, ki so prejemali filgrastim, so zelo pogosto poročali o trombocitopeniji.
Thrombocytopenia has been reported in patients treated with the ZALTRAP/FOLFIRI regimen.
Pri bolnikih, zdravljenih s shemo ZALTRAP/FOLFIRI, je bila opisana trombocitopenija.
Thrombocytopenia has been reported very commonly in patients receiving filgrastim.
Pri bolnikih, ki so dobivali filgrastim, so zelo pogosto poročali o trombocitopeniji.
Thrombocytopenia has been reported very commonly in patients receiving filgrastim.
Pri bolnikih, ki so prejemali filgrastim, so zelo pogosto poročali o trombocitopeniji.
Thrombocytopenia in patients with a positive in-vitro aggregation test in the presence of enoxaparin,
trombocitopenija pri bolnikih s pozitivnim testom agregacije in vitro v prisotnosti enoksaparina,
Thrombocytopenia is likely to reoccur in ITP patients upon discontinuation of treatment with eltrombopag.
Po prekinitvi zdravljenja z eltrombopagom se trombocitopenija lahko ponovi.
Thrombocytopenia Leukocytosis
trombocitopenija levkocitoza
Thrombocytopenia Neutropenia Anaemia Lymphopenia
trombocitopenija nevtropenija anemija limfopenija
Thrombocytopenia occurred in 27.0% of patients who received Pom + LD-Dex, and 26.8% of patients who received HD-Dex.
Trombocitopenija se je pojavila pri 27,0 % bolnikov, ki so prejemali Pom + NO-deks in pri 26,8 % bolnikov, ki so prejemali VO-deks.
Thrombocytopenia occurring after first exposure to a GPIIb/IIIa inhibitor may be explained by the fact that antibodies are naturally present in some normal individuals.
Trombocitopenijo, ki se pojavi po prvi izpostavljenosti zaviralcu GPIIb/IIIa, je mogoče pojasniti s tem, da so protitelesa pri nekaterih zdravih osebah naravno prisotna.
Thrombocytopenia or coagulation defects;
trombocitopenija ali motnje strjevanja krvi;
Thrombocytopenia or decreased platelet counts were reported in 24.9% of patients in clinical studies with trastuzumab emtansine and was the most common adverse reaction leading to treatment discontinuation (2.6%).
Trombocitopenijo ali zmanjšano število trombocitov so v kliničnih študijah s trastuzumabom emtanzinom zabeležili pri 24,9 % bolnikov in to je bil najpogostejši neželeni učinek, ki je povzročil prenehanje zdravljenja (2,6 %).
Thrombocytopenia or functional platelet defects
trombocitopenija ali okvare delovanja trombocitov
Thrombocytopenia sometimes with purpura
trombocitopenija, včasih s purpuro
Thrombocytopenia sometimes with purpurah
trombocitopenija, včasih s purpuroh
Thrombocytopenia Splenic rupture
Trombocitope nija raztrganje vranice
Thrombocytopenia typically occurs between the 5th and the 21st day following the beginning of treatment with enoxaparin sodium.
Trombocitopenija se običajno pojavi med 5. in 21. dnem po začetku zdravljenja z natrijevim enoksaparinatom.
Thrombocytopenia was generally reversible with dose reduction or dose interruption.
Po znižanju odmerka ali prekinitvi zdravljenja je trombocitopenija večinoma izzvenela.
Thrombocytopenia was Grade 3 or 4 in 20.7% of patients who received Pom + LD-Dex and in 24.2% who received HD-Dex.
Trombocitopenija 3. ali 4. stopnje se je pojavila pri 20,7 % bolnikov, ki so prejemali Pom + NO-deks, in pri 24,2 % tistih, ki so prejemali VO-deks.
Thrombocytopenia was reported in approximately 40% of subjects in clinical studies with Kyprolis and approximately 20% of subjects had grade ≥ 3 events.
O trombocitopeniji so poročali pri približno 40 % bolnikov v kliničnih študijah z zdravilom Kyprolis in približno 20 % bolnikov je imelo dogodke ≥ 3. stopnje.
Thrombocytopenia#
Trombocitopenija#
Thrombocytopenia*, Febrile neutropenia, Neutropenia*, Leukopenia*, Anaemia*, Lymphopenia*
trombocitopenija*, febrilna nevtropenija, nevtropenija *, levkopenija*, anemija*, limfopenija
Thrombocytopenia*, Febrile neutropenia, Neutropenia*, Leukopenia*, Anaemia*, Lymphopenia*
trombocitopenija*, febrilna nevtropenija, nevtropenija*, levkopenija*, anemija*, limfopenija
Thrombocytopenia*, Neutropenia*, Anaemia*
trombocitopenija*, nevtropenija*, anemija
Thrombocytopenia, anaemia and leukopenia
trombocitope nija, anaemija in levkopenija
thrombocytopenia, anaemia, leukopenia
febrilna nevtropenija, trombocitopenija, anemija, levkopenija
Thrombocytopenia, eosinophilia
Redki: trombocitopenija, eozinofilija
thrombocytopenia, eosinophilia
trombocitopenija, eozinofilija
Thrombocytopenia, leucopenia, eosinophilia
trombocitopen ija, levkopenija, eozinofilija
Thrombocytopenia, leucopenia, granulocytopenia
trombocitopenija, levkopenija, granulocitopenija
Thrombocytopenia, leukocytopenia Pancytopenia
trombocitopenija, levkopenija
Thrombocytopenia, Leukocytopenia, Neutropenia, Anaemia*
trombocitopenija, levkocitopenija, nevtropenija, anemija
Thrombocytopenia, leukopenia
levkopenija
Thrombocytopenia, leukopenia
trombocitopenija levkopenija
Thrombocytopenia, leukopenia
trombocitopenija, levkopenija
thrombocytopenia, leukopenia, anaemia, eosinophilia,
trombocitopenija, levkopenija, anemija, eozinofilija,
Thrombocytopenia, Leukopenia, Haemolysis*
trombocitopenija, levkopenija, hemoliza
thrombocytopenia, leukopenia, leukocytosis, haemorrhagic diathesis
trombocitopenija, levkopenija, levkocitoza, hemoragična diateza
thrombocytopenia, neutropenia (blood disorders)
trombocitopenija, nevtropenija (bolezni krvi)
thrombocytopenia, neutropenia, leukocytosis, polycythaemia, lymphopenia
trombocitopenija, nevtropenija, levkocitoza, policitemija, limfopenija
Thrombocytopenia, neutropenia, leukopenia, lymphopenia
trombocitopenija, nevtropenija, levkopenija, limfopenija
Thrombocytopenia, or decreased platelet counts, was commonly reported with trastuzumab emtansine and was the most common adverse reaction leading to treatment discontinuation (see section 4.8).
Trombocitopenija ali zmanjšano število trombocitov je bila med uporabo trastuzumaba emtanzina opisana pogosto in je bila najpogostejši neželeni učinek, ki je povzročil prenehanje zdravljenja (glejte poglavje 4.8).
Thrombocytopenia, purpura, leukopenia, anemia, methemoglobinemia, agranulocytosis
trombocitopenija, purpura, levkopenija, anemija, metemoglobinemija, agranulocitoza
Thrombocytopenia, sometimes with purpura
trombocitopenija, včasih s purpuro
Thrombocytopenia.
trombocitopenija;
Thrombocytopenia1
Trombocitopenij a11
Thrombocytopenia1
trombocitopenija1
Thrombocytopenia1
Trombocitopenija11
Thrombocytopenia11
Trombocitop enija11
Thrombocytopenia11
Trombocitopenij a11
Thrombocytopenia11
Trombocitopenija11
Thrombocytopenia: Severe (platelets less than 25 x 109/l) in 25 % of patients (8 % of courses); moderate (platelets between 25.0 and 50.0 x 109/l) in 25 % of patients (15 % of courses).
Trombocitopenija: Huda (število trombocitov manjše od 25 x 109/l) je bila pri 25 % bolnikov (8 % ciklusov), zmerna (število trombocitov med 25,0 in 50,0 x 109/l) pa pri 25 % bolnikov (15 % ciklusov zdravljenja).
Thrombocytopenia: Severe (platelets less than 25 x 109/l) in 25 % of patients (8 % of courses); moderate (platelets between 25.0 and 50.0 x 109/l) in 25 % of patients (15 % of courses).
Trombocitopenija: Huda oblika (število trombocitov manjše od 25 x 109/l) pri 25% bolnikov (8% ciklov zdravljenja); zmerna (število trombocitov med 25,0 in 50,0 x 109/l) pa pri 25% bolnikov (15% ciklov zdravljenja).
Thrombocytopenia: Severe (platelets less than 25 x 109/l) in 25 % of patients (8 % of courses); moderate (platelets between 25.0 and 50.0 x 109/l) in 25% of patients (15 % of courses).
Trombocitopenija: Huda oblika (število trombocitov manjše od 25 x 109/l) pri 25 % bolnikov (8 % ciklov zdravljenja); zmerna (število trombocitov med 25,0 in 50,0 x 109/l) pa pri 25 % bolnikov (15 % ciklov zdravljenja).
Thrombocytopenia: Severe thrombocytopenia (Grade 4 - platelets less than 10 x 109/l) occurred in 6 % of patients in 2 % of courses.
Trombocitopenija: Huda trombocitopenija (4. stopnje – število trombocitov manj kot 10 x 109/l) se je pojavila pri 6 % bolnikov v 2 % ciklusov.
Thrombocytopenia; Leukopenia, Pancytopenia
trombocitopenija, levkopenija, pancitopenija
Thrombocytopenia^, Anaemia, Leucopenias
nevtropenija^, trombocitopenija^, anemija, levkopenije
Thrombocytopeniaa Leukocytosisa
trombocitopenijaa levkocitozaa
Thrombocytopeniab
trombocitopenijab
Thrombocytopeniab,c
trombocitopenijab,c
thrombocytopenic purpura, pancytopenia, coagulopathy,
trombocitopenična purpura, pancitopenija, koagulopatija,
Thrombocytosis (see section 4.4)
trombocitoza (glejte poglavje 4.4)
Thromboembo lism (including pulmonary embolism and deep vein thrombosis) (see section 4.4)
Trombembolija (vključno s pljučno embolijo in globoko vensko trombozo) (glejte poglavje 4.4)
Thromboemboli sm (including pulmonary embolism and deep vein thrombosis) (see section 4.4)
Trombembolija (vključno s pljučno embolijo in globoko vensko trombozo) (glejte poglavje 4.4)
Thromboemboli sm (including pulmonary embolism and deep vein thrombosis) (see section 4.4.)
Trombembolija (vključno s pljučno embolijo in globoko vensko trombozo) (glejte poglavje 4.4)
thromboembolic
trombembolični in ishemični
Thromboembolic event
trombembolični dogodki
Thromboembolic event
trombembolični zaplet
thromboembolic events
pojav trombembolij e
Thromboembolic events - arterial and venous
Trombembolični dogodki – arterijski in venski
Thromboembolic events are commonly observed in women with advanced breast cancer and have been observed in clinical trials with Faslodex (see section 4.8).
Tromboembolične dogodke so pogosto opažali pri ženskah z napredovalim rakom dojke, opazili pa so jih tudi v kliničnih preskušanjih z zdravilom Faslodex (glejte poglavje 4.8).
Thromboembolic events ITP patients
Trombembolični dogodki Bolniki z ITP
Thromboembolic events Tabulated list of adverse reactions
Seznam neželenih učinkov v obliki preglednice
Thromboembolic events, including pulmonary embolism
trombembolični dogodki, vključno s pljučno embolijo
Thromboembolic events: In patients with VWD, there is a risk of occurrence of thromboembolic events, particularly in patients with known clinical or laboratory risk factors.
Trombembolični dogodki: Pri bolnikih s VWB obstaja tveganje pojava trombemboličnih dogodkov, zlasti pri bolnikih z znanimi kliničnimi ali laboratorijskimi dejavniki tveganja.
Thromboembolic reactions such as myocardial infarction (tight band around the chest with feeling like your heart is beating too fast), stroke (muscle weakness in the face, arm, or leg, trouble speaking or understanding others who are speaking), pulmonary embolism (shortness of breath, chest pain and fatigue), deep vein thromboses (pain and swelling in an extremity).
Trombembolični dogodki, kot so miokardni infarkt (občutek stiskanja okoli prsi in prehitrega utripanja srca), možganska kap (oslabelost mišic obraza, rok ali nog, težave z govorjenjem ali razumevanjem govorice drugih), pljučna embolija (kratka sapa, bolečine v prsih in utrujenost) in globoka venska tromboza (bolečina in otekanje okončine).
Thromboembolis m (including
Ortostatska hipotenzija10
Thromboembolis m (including
Trombembolija (vključno s
Thromboembolis m (including pulmonary embolism and deep vein thrombosis) (see section 4.4)
trombembolija (vključno s pljučno embolijo in globoko vensko trombozo) (glejte poglavje 4.4)
Thromboembolis m (including pulmonary embolism and deep vein thrombosis) (see section 4.4.)
Trombembolija (vključno s pljučno embolijo in globoko vensko trombozo) (glejte poglavje 4.4)
Thromboembolism
Trombombolija
Thromboembolism (including pulmonary
Trombembolija (vključno s pljučno
Thromboembolism (including pulmonary embolism and deep vein thrombosis) (see section 4.4.)
Trombembolija (vključno s pljučno embolijo in globoko vensko trombozo) (glejte poglavje 4.4)
Thromboembolism (increased risk of blood clots)*
tromboembolizem (povečano tveganje za nastanek krvnih strdkov)
Thromboembolism (problems with blood clots in the blood vessels) may occur very rarely, usually associated with severe OHSS.
Tromboembolični dogodki (tvorjenje strdkov v krvnih žilah) se pojavijo zelo redko, navadno v povezavi s hudo obliko sindroma hiperstimulacije jajčnikov.
Thromboembolism (pulmonary embolism, deep vein thrombosis)*
tromboembolija (pljučna embolija, globoka venska tromboza)
Thromboembolism, usually associated with severe OHSS (see section 4.4).
trombembolizem, običajno povezan s hudim OHSS (glejte poglavje 4.4)
Thrombolytics
Trombolitiki
Thrombophlebitis
vazospazem
Thrombophlebitis superficial
površinski tromboflebitis
thrombophlebitis, flushing, hot flush, hypertension, hypotension
tromboflebitis, zardevanje, vročinski obliv, hipertenzija, hipotenzija
Thrombophlebitis^
Tromboflebitis^
Thromboprophylaxis is recommended in patients being treated with Kyprolis in combination with dexamethasone or with lenalidomide and dexamethasone, and should be based on an assessment of the patient’s underlying risks and clinical status.
Za bolnike, ki prejemajo zdravilo Kyprolis v kombinaciji z deksametazonom ali z lenalidomidom in deksametazonom, je priporočljiva tromboprofilaksa, ki mora temeljiti na oceni bolnikovih osnovnih tveganj in kliničnega stanja.
thrombosis
embolija,
thrombosis
mestu
Thrombosis
tromboza
Thrombosis (blood clot) is an uncommon side effect (may affect up to 1 in 100 people) which may result in serious or fatal complications such as heart attack.
Tromboza (krvni strdek), občasen neželen učinek (pojavi se lahko pri največ 1 od 100 bolnikov), ki ima lahko za posledice resne zaplete, kakršen je srčni infarkt.
Thrombosis includes coronary artery thrombosis (blood clot in the heart arteries or within a stent being felt as a heart attack which can also be fatal) and/or thrombosis in the catheter, both of which are rare (may affect up to 1 in 1,000 people).
Tromboza vključuje trombozo koronarne arterije (krvni strdek v srčni arteriji ali znotraj stenta, kar se čuti kot srčni napad, ki je prav tako lahko smrten) in/ali trombozo v katetru, oba pojava sta redka (pojavita se lahko pri največ 1 od 1.000 bolnikov).
thrombosis) (see
trombozo)
thrombosis) (see
trombozo) (glejte
thrombosis) (see
vensko trombozo)
Thrombosis*; Pulmonary embolism*
tromboza*; pljučni embolizem
Thrombosis/embolism*
tromboza/embolija
Thrombotic
Trombotična
Thrombotic and embolic events Arterial thromboembolic events
Trombotični in embolični dogodki Arterijski trombembolični dogodki
Thrombotic events can be a risk in this population and this possibility should be carefully weighed against the benefit to be derived from the treatment.
V tej skupini bolnikov lahko trombotični dogodki predstavljajo tveganje, zato je treba to možnost skrbno pretehtati glede na korist zdravljenja.
Thrombotic events have been reported in neonatal and infant subjects undergoing cardiac bypass procedures while receiving off-label high doses of another C1 inhibitor product (up to 500 Units/kg) to prevent capillary leak syndrome.
O trombotičnih dogodkih so poročali pri novorojenčkih in dojenčkih, ki so za neodobrene indikacije prejemali velike odmerke kakega drugega zaviralca C1 (do 500 enot/kg) za preprečevanje sindroma zvečane prepustnosti kapilar med posegi na srcu z zunajtelesnim krvnim obtokom.
Thrombotic events were reported in 5 patients, none of which were on antithrombotic therapy at the time of the event, and in each of these cases, the thrombotic event could be attributed to the underlying medical condition of the patient.
O trombotičnih dogodkih so poročali pri 5 bolnikih, ki v času dogodka niso prejemali antitrombotične terapije, in pri vsakem izmed teh primerov so trombotični dogodek lahko pripisali osnovni bolnikovi bolezni.
Thrombotic microangiopathy (1)
trombotična mikroangiopatija (1)
Thrombotic microangiopathy (including thrombotic thrombocytopenic purpura and haemolytic uraemic syndrome)
trombotična mikroangiopatija (vključno s trombotično trombocitopenično purpuro in hemolitično- uremičnim sindromom)
Thrombotic microangiopathy (including thrombotic thrombocytopenic purpura and haemolytic uraemic syndrome) †
trombotična mikroangiopatija (vključno s trombotično trombocitopenično purpuro in hemolitično- uremičnim sindromom)
Thrombotic Microangiopathy (TMA)
Trombotična mikroangiopatija (TMA – thrombotic microangiopathy)
Thrombotic microangiopathy (TMA) has been reported in clinical trials of pazopanib as monotherapy, in combination with bevacizumab, and in combination with topotecan (see section 4.8).
V kliničnih preskušanjih, v katerih so preučevali pazopanib v monoterapiji, v kombinaciji z bevacizumabom oziroma v kombinaciji s topotekanom, je bila opisana trombotična mikroangiopatija (TMA) (glejte poglavje 4.8).
Thrombotic microangiopathy including thrombotic thrombocytopenic purpura/ haemolytic uraemic syndrome3
trombotična mikroangio- patija, vključno s trombotično trombocito- penično purpuro / hemolitično- uremičnim sindromom3
Thrombotic microangiopathy including thrombotic thrombocytopenic purpura/haemolytic uraemic syndrome#
trombotična mikroangiopatija, vključno s trombotično trombocitopenično purpuro/hemolitično- uremičnim sindromom#
Thrombotic microangiopathy including thrombotic thrombocytopenic purpura/haemolytic uraemic syndrome*
trombotična mikroangiopatija vključno s trombotično trombocitopenično purpuro/hemolitičnim uremičnim sindromom
thrombotic microangiopathy including thrombotic thrombocytopenic purpura/haemolytic uraemic syndrome*
trombotična mikroangiopatija, vključno s trombotično trombocitopenično purpuro/hemolitično-uremičnim sindromom
thrombotic microangiopathya,b
pljučna hipertenzijaa, perforacija nosnega pretinaa
Thrombotic thrombocytopenic purpura (TTP) (see section 4.4), aplastic anaemia, pancytopenia, agranulocytosis, severe thrombocytopenia, acquired haemophilia A, granulocytopenia, anaemia
trombotična trombocitopeničn a purpura (TTP) (glejte poglavje 4.4), aplastična anemija, pancitopenija, agranulocitoza, huda trombocitopenija, pridobljena hemofilija A, granulocitopenija, anemija
Thrombotic thrombocytopenic purpura (TTP) (see section 4.4), aplastic anaemia, pancytopenia, agranulocytosis, severe thrombocytopenia, acquired haemophilia A, granulocytopenia, anaemia
trombotična trombocitopenična purpura (TTP) (glejte poglavje 4.4), aplastična anemija, pancitopenija, agranulocitoza, huda trombocitopenija, pridobljena hemofilija A, granulocitopenija, anemija
Thrombotic thrombocytopenic purpura (TTP) (see section 4.4), aplastic anaemia, pancytopenia, agranulocytosis, severe thrombocytopenia, granulocytopenia, anaemia
trombotična trombocitopenična purpura (TTP) (glejte poglavje 4.4), aplastična anemija, pancitopenija, agranulocitoza, huda trombocitopenija, granulocitopenija, anemija
Thrombotic thrombocytopenic purpura (TTP) (see section 4.4), bone marrow failure*, aplastic anaemia, pancytopenia, bicytopenia*, agranulocytosis, severe thrombocytopenia, acquired haemophilia A, granulocytopenia, anaemia, haemolytic anaemia in patients with glucose-6-phosphate dehydrogenase (G6PD) deficiency* (see section 4.4)
Trombotična trombocitopenična purpura (TTP) (glejte poglavje 4.4), odpoved kostnega mozga*, aplastična anemija, pancitopenija, bicitopenija*, agranulocitoza, huda trombocitopenija, pridobljena hemofilija A, granulocitopenija, anemija, , hemolitična anemija pri bolnikih s pomanjkanjem glukoza-6-fosfat- dehidrogenaze (G6PD)* (glejte poglavje 4.4)
Thrombotic thrombocytopenic purpura (TTP) (see section 4.4), bone marrow failure*, aplastic anaemia, pancytopenia, bicytopenia*, agranulocytosis, severe thrombocytopenia, acquired haemophilia A, granulocytopenia, anaemia, haemolytic anaemia in patients with glucose-6-phosphate dehydrogenase (G6PD) deficiency* (see section 4.4)
Trombotična trombocitopenična purpura (TTP) (glejte poglavje 4.4), odpoved kostnega mozga*, aplastična anemija, pancitopenija, bicitopenija*, agranulocitoza, huda trombocitopenija, pridobljena hemofilija A, granulocitopenija, anemija, hemolitična anemija pri bolnikih s pomanjkanjem glukoza- 6-fosfat-dehidrogenaze (G6PD) * (glejte poglavje 4.4)
Thrombotic thrombocytopenic purpura (TTP) (see section 4.4), bone marrow failure*, aplastic anaemia, pancytopenia, bicytopenia*, agranulocytosis, severe thrombocytopenia, acquired haemophilia A, granulocytopenia, anaemia, haemolytic anaemia in patients with glucose-6-phosphate dehydrogenase (G6PD) deficiency* (see section 4.4)
Trombotična trombocitopenična purpura (TTP) (glejte poglavje 4.4), odpoved kostnega mozga*, aplastična anemija, pancitopenija, bicitopenija*, agranulocitoza, huda trombocitopenija, pridobljena hemofilija A, granulocitopenija, anemija, hemolitična anemija pri bolnikih s pomanjkanjem glukoza- 6-fosfat-dehidrogenaze (G6PD)* (glejte poglavje 4.4)
Thrombotic Thrombocytopenic Purpura (TTP) has been reported very rarely following the use of clopidogrel, sometimes after a short exposure.
O trombotični trombocitopenični purpuri (TTP) so po uporabi klopidogrela poročali zelo redko, včasih po kratki izpostavljenosti.
Thrombotic/Thromboembolic complications
Trombotični/trombembolični zapleti
Thrombotic/Thromboembolic events (TEEs)
Trombotični/Trombembolični dogodki
through 10.7 years in girls (n=369) and 10.6 years in boys (n=326), 9-15 years of age at time of vaccination (median follow-up of 10.0 years and 9.9 years, respectively);
v obdobju 10,7 leta pri deklicah (n = 369) in v obdobju 10,6 leta pri dečkih (n = 326), ob cepljenju starih od 9 do 15 let (mediani čas spremljanja deklic 10,0 leta in mediani čas spremljanja dečkov 9,9 leta);